Delivery Order SPE2DP20D0002-SPE2DP25F6741
Award Date 5/12/25
Potential Completion Date 5/20/25
Potential Value $165K
Federal Agency
Ultimate Awardee
Not listed NAICS Category
PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Not Competed
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Parsippany, NJ 07054, USA
Solicitation Procedures
Only One Source
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The U.S. Department of Defense's Medical Supply Chain, through the Defense Logistics Agency Troop Support Medical, awarded a $330,313.86 firm-fixed-price delivery order to Teva Pharmaceuticals USA, Inc. for Adenovirus Type 4 vaccine. The contract, issued on June 16, 2025, with an ultimate completion date of June 24, 2025, carries no set-aside designation and will be performed at Teva's facility in Parsippany, New Jersey. This delivery order represents a continuation of Teva's established role as...
- The U.S. Department of Defense's Medical Supply Chain awarded a $165,157 firm fixed-price delivery order to Teva Pharmaceuticals USA, Inc. for Adenovirus Type 4 vaccine, with an ultimate completion date of December 9, 2025. This delivery order was issued without a set-aside designation and represents work to be performed at Teva's primary facility in Parsippany, New Jersey. Teva, a subsidiary of Israeli-based Teva Pharmaceutical Industries Ltd., has served as a critical federal pharmaceutical...
- The Department of Defense's Medical Supply Chain awarded a $165,156.93 delivery order to Teva Pharmaceuticals USA, Inc. on December 1, 2025, for the supply of Adenovirus Type 4 vaccine. This firm-fixed-price delivery order, with an ultimate completion date of December 9, 2025, represents part of Teva's extensive portfolio supporting critical military immunization programs. The contract contains no set-aside designation and will be performed at Teva's manufacturing facility in Parsippany, New...
- The Department of Defense's Medical Supply Chain issued a delivery order valued at $1.98M to Teva Pharmaceuticals USA, Inc. for the supply of Adenovirus Type 4 vaccine, with an ultimate completion date of December 9, 2025. This firm-fixed-price delivery order, issued without set-aside designation, represents one of over 150 similar awards to Teva since 2023 under indefinite delivery contract vehicles managed by the Defense Logistics Agency Troop Support Medical. The Adenovirus Type 4 vaccine...
- The Department of Defense's Medical Supply Chain, functioning under defense operations, awarded a delivery order valued at approximately $826K to Teva Pharmaceuticals USA, Inc. for Adenovirus Type 4 vaccine. This contract, issued on August 12, 2025, with an ultimate completion date of August 26, 2025, carries a firm fixed price structure and was awarded without a set-aside designation. The work will be performed in Parsippany, New Jersey, where Teva maintains its headquarters as a subsidiary...
- The U.S. Department of Defense's Medical Supply Chain awarded a $1.32 million firm fixed-price delivery order to Teva Pharmaceuticals USA, Inc. for Adenovirus Type 4 vaccine, with performance scheduled for completion by December 9, 2025. This delivery order, issued without set-aside designation, represents one of over 150 awards Teva has received since 2023 under indefinite delivery contract vehicles, primarily through the Defense Logistics Agency Troop Support Medical. The vaccine will be...
- The U.S. Department of Defense Medical Supply Chain awarded a delivery order valued at $825,784.65 to Teva Pharmaceuticals USA, Inc. for Adenovirus Type 4 vaccine on September 8, 2025, with an ultimate completion date of September 23, 2025. The contract is structured as a firm fixed-price delivery order with no set-aside designation, and performance will be executed at Teva's facility in Parsippany, New Jersey. This delivery order is issued under a larger indefinite delivery vehicle and...
- The Defense Logistics Agency awarded Teva Pharmaceuticals USA, Inc. a firm fixed-price delivery order valued at $165,156.93 for Adenovirus Type 4 vaccine with an ultimate completion date of September 23, 2025. The contract, issued without a set-aside designation, is being performed in Parsippany, New Jersey, where Teva maintains its U.S. headquarters. This delivery order supports the Department of Defense's immunization programs and represents part of Teva's established role as a critical...
- The U.S. Defense Logistics Agency Troop Support Medical awarded a Firm Fixed Price Delivery Order contract to Teva Pharmaceuticals USA, Inc. for the delivery of Adenovirus Type 4 vaccines. The $135,747.00 contract has an August 25, 2020 completion date. Teva Pharmaceuticals USA, Inc. is a foreign-owned, for-profit manufacturer that has provided a range of pharmaceutical products, including vaccines, antiviral medications, and respiratory treatments, to federal customers such as the Department of...
- Teva Pharmaceuticals USA, Inc., headquartered in Parsippany, New Jersey, was awarded a delivery order valued at $825,784.65 for Adenovirus Type 4 vaccine on September 8, 2025, with an ultimate completion date of September 23, 2025. This firm-fixed-price contract, issued without a set-aside designation, supports the Medical Supply Chain within the Department of Defense. The delivery order represents a continuation of Teva's established role as a critical supplier of the Adenovirus Type 4...